NEW
YORK, Dec. 5, 2023 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a
patient-focused biopharmaceutical company, today announced it
has completed the manufacturing of its drug substance HT-KIT using
good laboratory practice (GLP). HT-KIT is an antisense
oligonucleotide that targets the proto-oncogene cKIT by inducing
mRNA frame shifting and already has Orphan Drug Designation from
the U.S. Food and Drug Administration (FDA). Hoth also recently
completed its Pre-IND meeting with FDA in November.
Hoth has now successfully completed manufacturing of the HT-KIT
drug substance in collaboration with WuXi STA Pharmaceutical. Hoth
plans to use the GLP drug substance in its upcoming pre-clinical
studies required for its investigational new drug (IND)
submission.
"With this important step now completed and with our Pre-IND
responses from FDA, Hoth is now ready to plan its IND-enabling
studies and pathway to HT-KIT's first-in-human clinical trial,"
stated Robb Knie, Chief Executive
Officer of Hoth.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing new generation therapies for unmet
medical needs. Hoth's pipeline development is focused to improve
the quality of life for patients suffering from skin toxicities
associated with cancer therapy, mast-cell derived cancers and
anaphylaxis, Alzheimer's Disease, atopic dermatitis and other
indications. To learn more, please
visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based
upon Hoth's current expectations which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates
Hoth may develop, and the labeling under any approval Hoth may
obtain; the timing and costs of clinical trials, the timing and
costs of other expenses; market acceptance of Hoth's products; the
ultimate impact of the current Coronavirus pandemic, or any other
health epidemic, on Hoth's business, its clinical trials, its
research programs, healthcare systems or the global economy as a
whole; Hoth's intellectual property; Hoth's reliance on third party
organizations; Hoth's competitive position; Hoth's industry
environment; Hoth's anticipated financial and operating results,
including anticipated sources of revenues; Hoth's assumptions
regarding the size of the available market, benefits of Hoth's
products, product pricing, timing of product launches; management's
expectation with respect to future acquisitions; statements
regarding Hoth's goals, intentions, plans and expectations,
including the introduction of new products and markets; and Hoth's
cash needs and financing plans. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. You should not place undue
reliance on these forward-looking statements, which include words
such as "could," "believe," "anticipate," "intend," "estimate,"
"expect," "may," "continue," "predict," "potential," "project" or
similar terms, variations of such terms or the negative of those
terms. Although Hoth believes that the expectations reflected in
the forward-looking statements are reasonable, Hoth cannot
guarantee such outcomes. Hoth may not realize its expectations, and
its beliefs may not prove correct. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including, without
limitation, market conditions and the factors described in the
section entitled "Risk Factors" in Hoth's most recent Annual Report
on Form 10-K and Hoth's other filings made with the U.S. Securities
and Exchange Commission. All such statements speak only as of the
date of this press release. Consequently, forward-looking
statements should be regarded solely as Hoth's current plans,
estimates, and beliefs. Hoth cannot guarantee future results,
events, levels of activity, performance or achievements. Hoth does
not undertake and specifically declines any obligation to update or
revise any forward-looking statements to reflect new information,
future events or circumstances or to reflect the occurrences of
unanticipated events, except as may be required by applicable
law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-it-has-successfully-completed-manufacturing-of-its-cancer-fighting-ht-kit-for-ind-enabling-studies-302005612.html
SOURCE Hoth Therapeutics, Inc.